Shin Nippon Biomedical Laboratories Targets FY2030 Sales of at Least JPY 70 Billion

• Shin Nippon Biomedical Laboratories targets fiscal 2030 revenue of at least 70 billion yen under its Transformation 2030 plan.
• Ordinary profit excluding currency effects is targeted at least 20 billion yen, with an ordinary profit margin of at least 28.5%.
• Fiscal 2026 forecasts call for revenue of 38 billion yen and ordinary profit excluding currency effects of 6 billion yen.
• The previous 2028 Vision targeted revenue of 50 billion yen, ordinary profit of 20 billion yen and a 40% margin.
• Return on equity and return on invested capital targets remain at least 10% each for fiscal 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shin Nippon Biomedical Laboratories Ltd. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.